RT @AurelieRheumo: BE OPTIMAL: BKZ in PsA Phase 3 RCT Data at 52 wks 700+ completed study ACR50: 53% PBO/BKZ, 54% BKZ,
Tweet Content
BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
Links
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…
http://bit.ly/3O4C0cK
Show on Archive Page
On
Display in Search Results
On
PDQ
Off